21 Ha’arba’a Street
367 articles with RedHill Biopharma
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
5/7/2020Pharma and life sciences companies from across the globe provide updates on their business and pipelines.
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
Abstract discussing Talicia pharmacokinetics and exposure-response presented as ePoster at Digestive Disease Week® (DDW) 2020
RedHill Biopharma Strengthens Coverage for Talicia® with Preferred Brand Position on Prime Therapeutics NetResults™ National Formulary
Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies
Six COVID-19 Patients Treated with RedHill’s Opaganib Under Compassionate Use Show Objective Clinical Improvement
Preliminary data in moderate-to-severe COVID-19 patients treated with opaganib show measurable clinical improvement in all six patients analyzed, including decreased requirement for supplemental oxygenation, higher lymphocyte counts and decreased CRP
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19RedHill is pursuing both RHB-107 and opaganib as potential treatments for COVID-19
RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide its investigational drug, RHB-107 (upamostat, WX-671) 1 , for testing in non-clinical studies for activity against SARS-CoV-2,
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
Objective improvement in first two patients treated with opaganib in Israel who have demonstrated measurable clinical improvement within days of treatment initiation, including decreased supplemental oxygen requirements, decreased C-reactive protein (CRP) levels and increased lymphocyte levels -- One patient was treated in the ICU, was considered for intubation, and was released within days of treatment-initiation -- Opaganib was administered in addition to standard-of-care, including hy
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use
Compassionate use approved by Israeli Ministry of Health; Additional patients expected to be treated in the coming days
Authorization of compassionate use granted by the Italian authorities, aided by RedHill’s strategic partner, Cosmo Pharmaceuticals N.V. (SIX: COPN) Approximately 160 patients with life-threatening clinical manifestations planned to be treated in three major hospitals in northern Italy A compassionate use program is ongoing in Israel where opaganib has been administered to the first patient at a leading hospital Discussions ongoing in the U.S. and other countries RedHill preparing for
RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and Aemcolo®
RedHill Biopharma Ltd., a specialty biopharmaceutical company focused on gastrointestinal diseases, provided a business update on proactive measures being taken with regard to the COVID-19 virus outbreak.
RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company focused on gastrointestinal diseases, today announced that Express Scripts has added Talicia® (omeprazole magnesium, amoxicillin and rifabutin)1 to its National Preferred Formulary as a preferred brand. RedHill recently launched Talicia® in the U.S., making Talicia® available through pharmacies nationwide.
Talicia® is the first and only FDA-approved rifabutin-based therapy for treatment of H. pylori infection designed as a first-line option to address the high and growing H. pylori resistance to clarithromycin
Under the license deal, RedHill is paying AstraZeneca $52.5 million up front with another non-contingent payment of $15 million 18 months after the deal closes.
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
RedHill to receive $30 million following closing to support its commercial operations, including the planned launch of Talicia® this quarter and the ongoing promotion of Aemcolo®
RedHill Biopharma Ltd., a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, announced that it is acquiring the global rights to Movantik® 1, excluding Europe, Canada and Israel, from AstraZeneca.
RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020,
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, today announced it has launched a nationwide H. pylori disease state educational field campaign led by its sales force, ahead of the planned U.S. launch of Talicia®1 later this quarter.